Targeted Cancer Therapy May Treat Resistant Gynecologic Cancers

PARP inhibitor veliparib might benefit women with BRCA gene mutation

Released: 21-Mar-2014 9:30 AM EDT
Embargo expired: 25-Mar-2014 7:30 AM EDT
Source Newsroom: Society of Gynecologic Oncology
Contact Information

Available for logged-in reporters only

Citations Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

Newswise — TAMPA, Fla.– An oral cancer drug improves outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies, suggests preliminary research. Gynecologic cancer cells that have a BRCA mutation appear to be sensitive to veliparib, which targets an enzyme called PARP (poly ADP-ribose polymerase), according to a Phase II study being presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer in Tampa, Fla., March 22-25.

PARP inhibitors prevent cancer cells from repairing themselves after experiencing DNA damage (for example from chemotherapy or radiation). Research has previously shown that veliparib is effective in combination with chemotherapy, but little data was available to indicate whether veliparib was effective as a single agent. Results of this multicenter trial suggest that it is.

“One criticism of the PARP drugs is they are not active in patients who have developed resistance to other therapies, but we found veliparib appears to be effective in some platinum-resistant patients with recurrent or persistent disease,” said Robert L. Coleman, MD, lead author of the study and professor and vice chair of clinical research at the University of Texas MD Anderson Cancer Center, Houston. “Most of these patients have run out of treatment options, and it is very hopeful to potentially have another therapy to offer them.”

In the study, 50 patients with BRCA gene mutations treated at one of 18 centers took veliparib by mouth twice a day. The median number of monthly treatment cycles was six (ranging from one to 22). Overall, 13 patients (26 percent) responded positively to the therapy, meaning the tumors shrank in size, including two patients in whom the tumors disappeared completely. In addition, disease was stabilized for more than four months in nearly half of the women (24).

“Patient recruitment can be a problem for many clinical trials, however, this one filled up very quickly, which reflects that women and their doctors understand that PARP inhibitors hold real promise,” said Dr. Coleman.

# # #

About SGO
The Society of Gynecologic Oncology (SGO) is a 501(c)6 national medical specialty organization of physicians and allied healthcare professionals who are trained in the comprehensive management of women with malignancies of the reproductive tract. The Society’s membership, totaling more than 1,800, is primarily comprised of gynecologic oncologists, as well as other related medical specialists including medical oncologists, radiation oncologists, nurses, social workers and pathologists. SGO members provide multidisciplinary cancer treatment including chemotherapy, radiation therapy, surgery and supportive care. www.sgo.org.


Comment/Share